[1] SALTER B S,WEINER M M,TRINH M A,et al.Heparin-induced thrombocytopenia:a comprehensive clinical review[J].J Am Coll Cardiol,2016,67(21):2519-2532.
[2] PRINCE M,WENHAM T.Heparin-induced thrombocytopaenia[J].Postgrad Med J,2018,94(1114):453-457.
[3] 颜明明,刘利月,戴婷婷,等.低分子肝素类药物的临床应用[J].中国医药指南,2018,16(18):39-40.
[4] 谷文静,张磊.肝素诱导的血小板减少症研究进展[J].临床血液学杂志,2017,30(1):5-7.
[5] RAUOVA L,AREPALLY G,PONCZ M,et al.Molecular and cellular pathogenesis of heparin-induced thrombocytopenia(HIT)[J].Autoimmun Rev,2018,17(10):1046-1052.
[6] 中国医师协会心血管内科医师分会血栓防治专业委员会.肝素诱导的血小板减少症中国专家共识(2017)[J].中华医学杂志,2018,98(6):408-417.
[7] WARKENTIN T E, SAFYAN E L, LINKINS L A. Heparin induced thrombocytopenia presenting as bilateral adrenal hemorrhages[J].N Engl J Med,2015,372(5):492-494.
[8] 任静,翟振国,门剑龙.肝素诱导的血小板减少症临床诊疗的循证进展[J].中华医学杂志,2017,97(46):3667-3670.
[9] 蒋媛,史桂玲,张惠娟,等.1例低分子肝素钙诱导血小板减少症的药学监护[J].医药导报,2017,36(4):406-409.
[10] SCHINDEWOLF M,SCHWANER S,WOLTER M,et al.Incidence and causes of heparin-induced skin lesions[J].CMAJ,2009,181(8):477-481.
[11] GREINACHER A.Heparin-induced thrombocytopenia[J].N Engl J Med,2015,373(19):1883-1884.
[12] KONSTANTINIDES S V,TORBICKI A,AGNELLI G,et al.Corrigendum to:2014 ESC guidelines on the diagnosis and manangement of acute pulmonary embolism[J].Eur Heart J,2014,36(39):2642.
[13] 朱愿超,赵紫楠,梁良,等.北京医院786例患者利伐沙班的应用分析[J].临床药物治疗杂志,2018,16(4):58-61.
[14] 郑煜,王齐兵,李晓哗.Ⅱ型肝素诱导血小板减少症的危险因素分析[J].上海医药,2016(37)9:46-48.